Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Express Scripts
McKinsey
Mallinckrodt
Medtronic
Dow
Harvard Business School

Last Updated: October 20, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Tucatinib

See Plans and Pricing

« Back to Dashboard

Development status for investigational drug Tucatinib: Sponsors, patents, clinical trial progress

Tucatinib is an investigational drug.

There have been 10 clinical trials for Tucatinib. The most recent clinical trial was a Phase 1 trial, which was initiated on August 1st 2019.

The most common disease conditions in clinical trials are Breast Neoplasms, Meningeal Neoplasms, and Rectal Neoplasms. The leading clinical trial sponsors are Seattle Genetics, Inc., Cascadian Therapeutics Inc., and Translational Breast Cancer Research Consortium.

There are six US patents protecting this investigational drug and one hundred and one international patents.

Recent Clinical Trials for Tucatinib
TitleSponsorPhase
A Study of Tucatinib vs. Placebo in Combination With Trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast CancerSeattle Genetics, Inc.Phase 3
A Safety, Tolerability, and Pharmacokinetic Study of Tucatinib in Healthy Japanese and Caucasian SubjectsSeattle Genetics, Inc.Phase 1
Tucatinib + Abemaciclib + Herceptin for HER2+ MBCEli Lilly and CompanyPhase 1

See all Tucatinib clinical trials

Clinical Trial Summary for Tucatinib

Top disease conditions for Tucatinib
Top clinical trial sponsors for Tucatinib

See all Tucatinib clinical trials

US Patents for Tucatinib

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Tucatinib   Start Trial Polymorphs of ARRY-380, a selective HER2 inhibitor and pharmaceutical compositions containing them Array BioPharma Inc. (Boulder, CO)   Start Trial
Tucatinib   Start Trial N4-phenyl-quinazoline-4-amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases Array Biopharma, Inc. (Boulder, CO)   Start Trial
Tucatinib   Start Trial Polymorphs of ARRY-380, a selective HER 2 inhibitor and pharmaceutical compositions containing them Array BioPharma Inc. (Boulder, CO)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Harvard Business School
Merck
Boehringer Ingelheim
Dow
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.